CRESCENT BIOPHARMA INC

CBIO is the ticker symbol for Catalyst Biosciences, Inc., a biopharmaceutical company. The stock represents equity ownership in the company and trades on the Nasdaq exchange. CBIO focuses on developing therapies for bleeding disorders and other serious medical conditions. As a biotech stock, its value is closely tied to clinical trial outcomes, regulatory decisions, and pipeline progress.

Recent performance for CBIO can be found in the price chart and performance metrics on this page, which show changes over various periods. Biotech stocks like CBIO often experience volatility driven by pipeline news, financing activities, and sector sentiment. For the latest price movement, refer to the live data displayed above.

Determining whether CBIO is overvalued or undervalued requires analyzing its financials, pipeline potential, and comparing valuation multiples to peers. Since CBIO may have no approved products or earnings, traditional metrics like P/E may not apply. Investors often use cash position, research progress, and market potential instead. Check the valuation section on this page for current metrics.

CBIO may be traded in pre-market and after-hours sessions through certain brokers, though liquidity is typically lower and spreads wider. Regular trading hours for Nasdaq-listed stocks are 9:30 AM to 4:00 PM ET. Extended-hours trading carries additional risks, and not all brokers offer it. For specific availability, check with your brokerage.

CBIO does not currently pay dividends. Biopharmaceutical companies often reinvest capital into research and development rather than distributing profits to shareholders. As a clinical-stage company, CBIO is more likely to use funds for pipeline advancement and operational needs. For the most up-to-date dividend information, refer to the dividend section on this page.

Key risks for CBIO include clinical trial failures, regulatory delays, cash burn, and dependence on financing. As a small-cap biotech, it may face intense competition, intellectual property challenges, and share dilution. Market sentiment toward biotech can also affect volatility. These factors can significantly impact the stock price and should be carefully considered.